These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28139840)

  • 1. Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.
    Hamzic S; Kummer D; Milesi S; Mueller D; Joerger M; Aebi S; Amstutz U; Largiader CR
    Clin Pharmacol Ther; 2017 Nov; 102(5):796-804. PubMed ID: 28139840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
    Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of pharmacogenetics in capecitabine efficacy and toxicity.
    Lam SW; Guchelaar HJ; Boven E
    Cancer Treat Rev; 2016 Nov; 50():9-22. PubMed ID: 27569869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of new SNPs associated with severe toxicity to capecitabine.
    Pellicer M; García-González X; García MI; Robles L; Grávalos C; García-Alfonso P; Pachón V; Longo F; Martínez V; Blanco C; Iglesias I; Sanjurjo M; López-Fernández LA
    Pharmacol Res; 2017 Jun; 120():133-137. PubMed ID: 28347776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
    de With M; van Doorn L; Maasland DC; Mulder TAM; Oomen-de Hoop E; Mostert B; Homs MYV; El Bouazzaoui S; Mathijssen RHJ; van Schaik RHN; Bins S
    Biomed Pharmacother; 2023 Mar; 159():114232. PubMed ID: 36630849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.
    García-González X; Cortejoso L; García MI; García-Alfonso P; Robles L; Grávalos C; González-Haba E; Marta P; Sanjurjo M; López-Fernández LA
    Oncotarget; 2015 Mar; 6(8):6422-30. PubMed ID: 25691056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of fluorouracil -based chemotherapy toxicity.
    Matsusaka S; Lenz HJ
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):811-21. PubMed ID: 25800061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
    Schmulenson E; Krolop L; Simons S; Ringsdorf S; Ko YD; Jaehde U
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):435-444. PubMed ID: 32852627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.
    Meulendijks D; van Hasselt JGC; Huitema ADR; van Tinteren H; Deenen MJ; Beijnen JH; Cats A; Schellens JHM
    Eur J Cancer; 2016 Feb; 54():120-130. PubMed ID: 26761784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.
    Ruiz-Pinto S; Pita G; Martín M; Nuñez-Torres R; Cuadrado A; Shahbazi MN; Caronia D; Kojic A; Moreno LT; de la Torre-Montero JC; Lozano M; López-Fernández LA; Ribelles N; García-Saenz JA; Alba E; Milne RL; Losada A; Pérez-Moreno M; Benítez J; González-Neira A
    Clin Pharmacol Ther; 2021 Feb; 109(2):462-470. PubMed ID: 32757270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
    Kummer D; Froehlich TK; Joerger M; Aebi S; Sistonen J; Amstutz U; Largiadèr CR
    Pharmacogenomics; 2015; 16(12):1367-77. PubMed ID: 26244261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
    Hamzic S; Kummer D; Froehlich TK; Joerger M; Aebi S; Palles C; Thomlinson I; Meulendijks D; Schellens JHM; García-González X; López-Fernández LA; Amstutz U; Largiadèr CR
    Pharmacol Res; 2020 Feb; 152():104594. PubMed ID: 31838077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine.
    Janssen JM; Jacobs BAW; Roosendaal J; Derissen EJB; Marchetti S; Beijnen JH; Huitema ADR; Dorlo TPC
    AAPS J; 2021 Jan; 23(1):23. PubMed ID: 33417061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine-induced Leukoencephalopathy.
    Yoshimura K; Tokunaga S; Daga H; Inoue M
    Intern Med; 2019 Feb; 58(4):621-622. PubMed ID: 30333392
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
    Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
    Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical henna for capecitabine induced hand-foot syndrome.
    Yucel I; Guzin G
    Invest New Drugs; 2008 Apr; 26(2):189-92. PubMed ID: 17885735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of gender on capecitabine toxicity in colorectal cancer.
    Ilich AI; Danilak M; Kim CA; Mulder KE; Spratlin JL; Ghosh S; Chambers CR; Sawyer MB
    J Oncol Pharm Pract; 2016 Jun; 22(3):454-60. PubMed ID: 26002954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile.
    Mercier C; Dupuis C; Blesius A; Fanciullino R; Yang CG; Padovani L; Giacometti S; Frances N; Iliadis A; Duffaud F; Ciccolini J
    Cancer Chemother Pharmacol; 2009 May; 63(6):1177-80. PubMed ID: 19107485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.